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Abstract
West Nile virus (WNV), a mosquito-borne flavivirus in the Japanese encephalitis antigenic group, has caused sporadic outbreaks in humans,
horses and birds throughout many of the warmer regions of Europe for at least 20 years. Occasional cases of West Nile encephalitis have
also been associated with infected blood transfusions and organ donations. Currently, WNV appears to be expanding its geographical range
in Europe and causing increasing numbers of epidemics/outbreaks associated with human morbidity and mortality. This brief review reports
on the current epidemic situation regarding WNV in Europe, highlighting the clinical, diagnostic and preventive measures available for
controlling this apparently emerging human pathogen.
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Introduction
West Nile virus (WNV) is a mosquito-borne flavivirus in the
Japanese encephalitis antigenic group. It was first isolated in
1937 from a febrile woman in Omogo in the West Nile district
of Uganda [1]. WNV has a natural transmission cycle in Culex
spp. mosquitoes and wild and captive birds [2]. In contrast,
humans and horses are incidental dead-end hosts [3]. The
enzootic/epizootic cycle is strictly linked to the period of
activity of the arthropod vectors, which, in Europe, results in a
season of WNV activity that, depending on the different
latitude, ranges from mid-June to mid-November [4,5]. Since
its first recognition in Uganda, the virus has gradually
dispersed, via migratory birds, out of Africa to the more
southerly regions of Europe, Asia, and Australasia [2]. This
review highlights some of the most relevant aspects of WNV
human infections in Europe.
Epidemiology of WNV in EU Member
Countries and Neighbouring Regions
Up to the mid-1990s, the dispersal of human WNV infections
in Europe was mainly associated with sporadic cases [5].
Initially, outbreaks involving significant numbers of cases
presenting with neuroinvasive disease were reported in 1994
in Algeria and in 1996 in Romania [5]. WNV was also
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introduced into the New York area of the USA in 1999, rapidly
spreading to four north-eastern states and disseminating
outwards in a wave across the entire country over subsequent
years [6]. Meanwhile, the virus continued to circulate in
Europe and Asia/Australasia [2]. The largest human outbreaks
occurred in Bucharest in 1996 (393 hospitalized cases; 17
deaths) and Russia in 1999 (318 human cases; 40 deaths) [7,8].
Three regions of the Russian Federation—Volgograd, Astrak-
chan, and Rostov—reported WNV fever/encephalitic activity.
Between 1999 and 2010, 928 human cases were identified in
the Volgograd area, and 322 and 40 in Astrakchan and Rostov,
respectively. Peak epidemic activity was reported in Volgograd
in 1999 (380 cases) and 2010 (413 cases) [9]. Concerning
other countries in the EU area, cases of WNV encephalitis
were initially recorded in horses in Italy (1998) and southern
France (2000)[10]. In Italy, the virus reappeared in association
with human cases of neurological disease in 2008 [11,12]. In
addition, different seropositivity rates have been reported for
horses, humans and birds in Spain [13,14] and Portugal [15,16],
with the first clinical cases of WNV-related disease being
reported in Spain for horses and humans in 2010 [17].
Evidence of WNV circulation among birds has been reported
in the UK since 2003, and in 2006 the use of sentinel chickens
corroborated the epidemiological data about WNV in the UK
by demonstrating actual seroconversion [18,19]. As far as the
remaining European countries are concerned, reports indi-
cated that blood donors were seronegative for WNV in Tyrol,
Austria [20] and in The Netherlands [21], whereas the
prevalence of anti-WNV neutralizing antibodies was very low
(0.03%) among blood donors in Germany. Nevertheless, a
recent evaluation of immunoglobulin preparations produced
from human plasma collected in Austria, Germany and the
Czech Republic indicated increasing WNV antibody titres in
preparations from 2009 and 2010, suggesting past WNV
exposure of just under 1% of the population of these three
central European countries [22].
In the last 2 years, WNV provoked large human epidemics
in the Balkan area, including Greece, Romania, Croatia, the
Former Yugoslav Republic of Macedonia, Kosovo, Montene-
gro, and Serbia. Additional European countries that were
affected by WNV circulation with human involvement during
the 2012 season were Italy and Hungary. During 2012, relevant
WNV activity was also detected in the Russian Federation,
Ukraine, Israel, Tunisia, Algeria, and the Occupied Palestinian
Territories, as reported by the European Centres for Disease
Control (ECDC) website on clinically apparent cases of WNV
in Europe in 2012 (http://www.ecdc.europa.eu/en/healthtopics/
west_nile_fever/West-Nile-fever-maps/Pages/index.aspx; the
most recent report was issued on 30 November 2012).
During 2012, North America experienced the worst outbreak
of WNV, the total number of human cases rising to 5387 and
that of deaths to 243 in the latest set of national data released
by the CDC on 11 December 2012. More than half of the
cases (2734) were of the more serious neuroinvasive form
(data from http://www.cdc.gov/ncidod/dvbid/westnile/surv&
control.htm; last accessed on 26 February 2013).
Limited phylogenetic analyses are currently available for
WNV isolates circulating in humans in Europe. In particular,
WNV lineage 2, which had previously been detected only in
birds and vectors in a range of European regions, was identified
in encephalitic and WNV fever cases in Russia in 2004, 2007,
and 2010 [9], in a Hungarian goshawk that died of encephalitis
in 2004 [23], and in humans with encephalitic disease during
the first outbreak in Greece in 2010 [24]. A complete genome
analysis performed in a WNV strain obtained during the Greek
outbreak showed high (99.6%) nucleotide identity with the
lineage 2 strain that emerged in Hungary in 2004 [25]. Very
recently, lineage 2 strains of WNV were also identified in two
human cases in distinct Italian locations; these strains were
closely related to each other and to those responsible for the
outbreaks that occurred in Greece and Hungary in 2010 and
2004, respectively [26,27]. The genetic diversity among the
diverse viral strains identified in vectors and birds over the
past 10 years in Europe is wide, including several different
phylogenetic clades [28]. Phylogenetic interpretation of these
data has suggested two possible explanations for the dispersal
patterns and survival strategies of WNV in this region of
Europe. First, each year, the viruses circulating in Europe are
introduced via migratory birds arriving each spring from Africa,
and the introduced viruses do not survive at a significant level
in Europe over the winter period. Second, the genetic
variation may be the result of selective pressures exerted via
innate and acquired immunological pathways in vertebrate
hosts on currently circulating viruses. Whether or not either
of these interpretations is correct will require further
investigation. The emergence of an exotic WNV strain of
lineage 2 in a Hungarian goshawk in 2004 emphasizes the role
of migrating birds in introducing new viruses to Europe [23].
As the goshawk is not a migratory species, the African WNV
strain must have successfully adapted to local mosquito
vectors before causing local transmission. As far as the genetic
variation of human-derived WNV strains is concerned, three
independent studies reported phylogenetic investigation of
WNV human isolates in Europe. First, Rossini et al. [29]
showed that seven strains derived from human patients in
2008 and 2009 in Italy clustered closely with two mosquito
vector-derived isolates collected in 2008 in northern Italy.
Second, Barzon et al. described a novel lineage, 1a (designated
the Livenza strain), which correlated with the western
Mediterranean subtype causing most of the human cases
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detected in north-eastern Italy in 2011 and that was divergent
from the isolates reported 2 years earlier [30]. More recently,
another report showed that two different human isolates
obtained in 2011 from Veneto and Sardinia were genetically
diverse [31]. These data support the hypothesis of seasonal
introduction of WNV variants within Europe.
Clinical Issues
Most humans infected with WNV remain asymptomatic [2].
Approximately 20–40% of infected humans develop symptoms,
the vast majority of which range from a mild flu-like syndrome,
West Nile fever (WNF), to severe West Nile encephalitic
disease (WNED). This severe condition involves <1% of the
infected patients. The neurological disease usually encom-
passes three different syndromes: meningitis, encephalitis, and
acute flaccid paralysis [3]. The clinical characteristics of the
symptomatic cases of WNV infection reported in Europe
correspond mainly with those indicated above. A recent
update on the Greek epidemic reported >250 WNED cases in
2010 and 2011, with a fatality rate of 15% [32]. Between 2008
and 2011, the case-fatality rate reported in Italy for WNED
was 16% [33]. The actual case-fatality rate reported by the
CDC in the USA ranges from 3% to 15% (http://www.cdc.gov/
ncidod/dvbid/westnile/qa/cases.htm; last accessed on 27 Feb-
ruary 2013). In 2010, only seven clinically evident cases of
WNV infection were described in Italy (four WNF and three
WNED) [34], whereas Barzon et al. reported 13 cases, from
the same area in northern Italy, early in 2012 (five WNED,
three WNF, and five RNA-positive blood donors, mainly
caused by the Livenza 1a autochthonous strain) [35]. In the
Volgograd region, 50 cases with neurological involvement
were reported among 413 cases in 2010, including five fatalities
(Fyodorova, personal communication). One of the most
clinically relevant features of WNV infection in humans is the
large percentage of infected asymptomatic subjects, which is
usually reported being >80% of the total of individuals infected
[3]. However, the viral load present in these asymptomatic
subjects is not known. Nevertheless, in at least some of these
asymptomatic individuals, infectious virus is clearly present and
able to be transmitted via blood transfusion and organ
transplantation [36]. During the recent past, several cases of
WNV transmission related to transfusion of infected blood,
solid organ transplants (SOTs) or haematopoietic stem cells
have been reported in the USA [37]. Moreover, a recent
report demonstrated that WNV-specific IgM antibodies were
present in the Italian SOT donor population in 2010, implying a
likelihood of WNV transmission via organ donation in the
absence of preventive screening procedures [38]. In addition,
during the past 4 years, transmission of WNV via infected
transfused blood and/or organs has occurred in Europe, where
at least two different episodes have been reported (involving
six recipient patients) of WNV transmission generated by solid
organ transplantion [39,40]. The clinical diagnosis of WNED is
mainly based on the presence of characteristic symptoms that
suddenly appear in an epidemiologically exposed individual. On
the other hand, most cases of WNF remain undiagnosed or
can be categorized as so-called ‘summer fevers of unknown
origin’, given the mild clinical presentation, which rarely leads
to laboratory diagnosis [36].
Diagnostic Issues
Several different tools are presently available for the labora-
tory diagnosis of WNV infections [11]. In the case of suspected
WNED, the diagnosis is generally performed by the detection
of viral RNA in serum or cerebrospinal fluid (CSF) samples
with real time RT-PCR assays. Identification of the WNV
genome in the CSF or serum during the acute stage of
neurological involvement is generally considered to be a
confirmatory diagnostic parameter [41]. When viral RNA is
not detectable in the CSF, the detection of a specific IgM
immune response, either in the CSF or in serum, is accepted as
a reliable diagnostic indicator of the early stage of an infection
that can subsequently be confirmed by the detection of IgG
seroconversion (indicated by a four-fold or greater increase in
the level of IgG in the serum) during the convalescent phase of
the infection. The detection of WNV-specific antibodies can be
achieved by immunofluorescence assay and enzyme immuno-
assay [11]. One important practical weakness of these
techniques is the limited specificity resulting from the wide-
spread immunological cross-reactions among flaviviruses [42].
In order to overcome this lack of specificity, a confirmatory
assay performed with the plaque reduction neutralization
technique is generally advisable; however, the plaque reduction
neutralization technique is complex to perform, requires viable
virus isolates, and must be performed under BSL3 safety
condition [43]. As a consequence, only a few laboratories in
Europe are capable of routinely performing this confirmatory
test. The detection of a specific IgG response, mainly by
enzyme immunoassay, has value in the context of the
epidemiological studies that are warranted to monitor the
potentially evolving circulation of WNV among humans in
Europe. As an alternative, the isolation of WNV in cell cultures
from CSF and serum samples could be performed, but it must
be underlined that this is a scarcely sensitive assay, although it
is the most specific method, and it requires the continuous
availability of cell cultures under BSL3 conditions [44]. For
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these reasons, the isolation techniques are generally per-
formed only in research laboratories.
Concerning blood and organ donation, two different com-
mercially licensed tests are available for the screening of WNV
RNAs in donors [45,46]. Both methods are fully automated and
based on genome amplification techniques: the first uses real
time RT-PCR, and the second is based on transcription-
mediated amplification technology. These tests have a sensi-
tivity in the range of 10–40 genome copies/mL for the standard
WNV preparations derived from lineage 1 American isolates.
A major concern relating to the sensitivity of these tests for the
detection of WNV in Europe is the well-documented genetic
variability of the European strains, which contrasts with
American isolates, and the recent emergence of human
infections caused by WNV lineage 2 in Europe [26,29,31,47].
Therapy
There are currently no specific therapeutic treatments for
WNV infections [3], although high-throughput library and
compound screening activities are being undertaken in a
search for potential inhibitors of WNV infection under the 7th
EU Framework grant agreement number 260644. WNED
cases usually require intensive-care unit-related interventions
and life support therapy, followed by comprehensive rehabil-
itation cycles, in order to achieve the best recovery [3].
Experimental treatment of severe cases with large doses of
either hyperimmune plasma or purified immunoglobulins with
elevated titres of antibodies against WNV has been described
in selected cases of infection acquired via SOTs [39]. Although
such treatments are currently rarely undertaken, there is a
body of opinion in favour of encouraging the development of
this type of procedure for treating WNED.
Prevention
Within Europe, the quality of data concerning the circulation
of WNV among vector birds and humans varies from country
to country. Moreover, there are currently no common
surveillance or health policies for the application of control
measures in the event of disease outbreaks. Accordingly, as
precise definition of viral circulation in vectors and vertebrate
hosts, including humans, within defined geographical areas is
essential for the definition of the risk of WNV transmission via
mosquitoes, blood transfusion, and organ donations, the
ECDC recently introduced a web-based publication of the
WNV-affected areas (available at http://ecdc.europa.eu/en/
healthtopics/west_nile_fever/west-nile-fever-maps/pages/index.
aspx; last accessed on 1 December 2012). On the basis of
these risk maps and the local surveillance data, each European
country should now be able to define the areas and seasons for
the implementation of vector control measures and laboratory
screening of blood and organ donations, to reduce the risk of
human-to-human transmission of WNV. As mentioned, two
different commercially licensed tests are currently available for
the screening of WNV RNA in donors [45,46]. As far as the
immune prophylaxis of human WNV disease is concerned, no
licensed vaccination options for WNV are currently available,
although some vaccine preparation candidates have recently
been evaluated [41], and several licensed equine vaccines
against WNV already exist [11,48]. At present, most of the
efforts to develop a licensed human vaccine have stalled. A
commercial US vaccine preparation went successfully through
a phase II trial some years ago, but, for reasons related to
market uncertainty regarding the potential target population
that should receive the vaccine, the manufacturer decided to
stop the development process [49]. The recent reports of the
possible development of kidney damage among younger
WNV-infected subjects [50] and the excretion of WNV from
the urine of WNED patients years after their apparent
recovery from the disease [51] could create a completely
different set of priorities for a vaccine against WNV [49].
Conclusions
WNV appears to be expanding its geographical range in
Europe and in the rest of the world, causing increasing
numbers of outbreaks associated with human morbidity and
mortality. Multiple de novo introduction of unrelated WNV
strains has been demonstrated in Europe, raising concerns
about the potential emergence of strains with increased
virulence, and the limitations of current diagnostic tests in
identifying novel and unexpected WNVs. Given this continuing
unpredictability and the rapid development of epidemics,
timely surveillance for WNV infection is needed on an
EU-wide scale. This includes veterinary and entomological
surveillance, as well as molecular surveillance of emerging
strains.
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